A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer

Zhang L(2020)The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review Ann Transl Med. 8 1526-98

Zhang M(2016)PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis Crit Rev Oncol Hematol. 100 88-39

Xu J(2016)PD-L1 expression in human cancers and its association with clinical outcomes Onco Targets Ther. 9 5023-800

Li S(2002)Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med. 8 793-33

Chen Y(2016)The PD1:PD-L1/2 pathway from discovery to clinical implementation Front Immunol. 7 550-13

Wang W(2016)Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer N Engl J Med. 375 1823-502

Gandini S(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med. 373 1803-7

Massi D(2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Lancet. 389 2492-32

Mandalà M(2016)Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study J Clin Oncol. 34 2460-8

Wang X(2015)Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med. 372 2521-12

Zhang L(2020)The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review Ann Transl Med. 8 1526-98

Zhang M(2016)PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis Crit Rev Oncol Hematol. 100 88-39

Xu J(2016)PD-L1 expression in human cancers and its association with clinical outcomes Onco Targets Ther. 9 5023-800

Li S(2002)Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med. 8 793-33

Chen Y(2016)The PD1:PD-L1/2 pathway from discovery to clinical implementation Front Immunol. 7 550-13

Wang W(2016)Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer N Engl J Med. 375 1823-502

Gandini S(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med. 373 1803-7

Massi D(2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Lancet. 389 2492-32

Mandalà M(2016)Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study J Clin Oncol. 34 2460-8

Wang X(2015)Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med. 372 2521-12